3 Largest Private Healthcare Group, Affordable Cardiac Care Hospital Group and Ingredients and Formulations Maker Stocks With a Strong Future Roadmap: Apollo Hospitals Enterprise, Narayana Hrudayalaya and Granules India

Hospital chain, cardiac care and API stocks bring together companies with a visible plan for the years ahead. Apollo Hospitals Enterprise, Narayana Hrudayalaya and Granules India cover the largest private healthcare group, an affordable cardiac care hospital group and an ingredients and formulations maker.

This list covers three hospital chain, cardiac care and API stocks with complete current figures: Apollo Hospitals Enterprise, Narayana Hrudayalaya and Granules India. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hospital Chain, Cardiac Care and API Stocks?

Hospital chain, cardiac care and API stocks are listed healthcare companies that run large hospital networks and make ingredients and finished medicines. Their earnings depend on bed capacity, patient volumes, specialty mix and export demand.

Hospital Chain, Cardiac Care and API Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing hospital chain, cardiac care and API stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital chain, cardiac care and API stocks can use the coming numbers to test whether growth is holding.

Why Do Hospital Chain, Cardiac Care and API Stocks Have a Strong Roadmap in India?

Hospital chain, cardiac care and API stocks have a strong roadmap in India because rising insurance cover, medical travel and demand for advanced treatment keep lifting admissions and healthcare spending.

• Bed additions. New capacity adds patient volumes.
• Specialty care. Advanced treatments raise revenue per patient.
• Ingredient volumes. High-volume molecules support steady output.

Why Apollo Hospitals Enterprise Features Among These Hospital Chain, Cardiac Care and API Stocks

Among the hospital chain, cardiac care and API stocks on this list, Apollo Hospitals Enterprise is India's largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.

Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6.

Roadmap: The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.

What to watch: Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.

Why Narayana Hrudayalaya Features Among These Hospital Chain, Cardiac Care and API Stocks

Among the largest hospital group shares on this list, Narayana Hrudayalaya, widely known as Narayana Health, is a Bengaluru-based hospital group built around affordable cardiac care that now covers multiple specialities across India and also operates in the Cayman Islands.

Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%.

The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6.

Roadmap: Growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.

What to watch: Keep an eye on occupancy in newly added beds and the payor mix between insurance and cash patients.

Why Granules India Features Among These Hospital Chain, Cardiac Care and API Stocks

Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

Apollo Hospitals Enterprise vs Narayana Hrudayalaya vs Granules India on Key Financials

The table below sets the three hospital chain, cardiac care and API stocks side by side on revenue, profit and margin, using reported figures.

Apollo Hospitals Enterprise posts the highest return on equity in this group at 20.5%. Apollo Hospitals Enterprise has the largest FY26 revenue at Rs 25,420 crore, and Narayana Hrudayalaya shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with hospital chain, cardiac care and API stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Hospital Chain, Cardiac Care and API Stocks

Every theme carries risks that deserve a check before any decision. For these hospital chain, cardiac care and API stocks, the main points are: Long-term largest hospital group shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Capacity timing. New beds take time to mature.
• Pricing. Health care pricing rules can affect revenue.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hospital chain, cardiac care and API stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hospital Chain, Cardiac Care and API Stocks

Hospital chain, cardiac care and API stocks suit investors who prefer to study business strength before price moves. Apollo Hospitals Enterprise, Narayana Hrudayalaya and Granules India each have a clear plan to expand. Based on the 26 October 2026 close, Apollo Hospitals Enterprise trades at Rs 7,844, Narayana Hrudayalaya at Rs 1,662.3 and Granules India at Rs 820.55. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these hospital chain, cardiac care and API stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track hospital chain, cardiac care and API stocks, set price alerts and get research-backed stock ideas.

What are hospital chain, cardiac care and API stocks?

Ans. Hospital chain, cardiac care and API stocks are listed healthcare companies that run large hospital networks and make ingredients and finished medicines. Their earnings depend on bed capacity, patient volumes, specialty mix and export demand. This list looks at three of them, Apollo Hospitals Enterprise, Narayana Hrudayalaya and Granules India, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which hospital chain, cardiac care and API stocks are covered in this list?

Ans. This list covers Apollo Hospitals Enterprise, Narayana Hrudayalaya and Granules India. Based on the 26 October 2026 close, Apollo Hospitals Enterprise traded at Rs 7,844, Narayana Hrudayalaya at Rs 1,662.3 and Granules India at Rs 820.55. Their return on equity ranges from 11.7% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 21.0%.

Why do hospital chain, cardiac care and API stocks have a strong future roadmap in India?

Ans. Hospital chain, cardiac care and API stocks have a strong roadmap in India because rising insurance cover, medical travel and demand for advanced treatment keep lifting admissions and healthcare spending. The main drivers are as follows. Bed additions. New capacity adds patient volumes. Specialty care. Advanced treatments raise revenue per patient. Ingredient volumes. High-volume molecules support steady output. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Apollo Hospitals Enterprise performed financially?

Ans. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.

How has Narayana Hrudayalaya performed financially?

Ans. Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What risks should investors check before buying hospital chain, cardiac care and API stocks?

Ans. Investors should check a few risks before buying hospital chain, cardiac care and API stocks. Capacity timing. New beds take time to mature. Pricing. Health care pricing rules can affect revenue. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hospital chain, cardiac care and API stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.